© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 17, 2022
On November 17, the US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.
November 14, 2022
November 13, 2022
Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.
November 12, 2022
High Relapse Rate After Discontinuing Antiviral Therapy for HBV Patients With Cirrhosis
Insomnia, Hypersomnia Identified as Symptoms of Long COVID Syndrome
Study Evaluates Insomnia and Suicidality Among Healthcare Workers During COVID-19 Pandemic